Search academic texts

Registration Number

0225U003432, (0122U002448) , R & D reports

Title

Improving the effectiveness of treatment of neuroblastoma, Ewing's sarcoma and brain tumors in children by double transplantation of autologous hematopoietic cells

popup.stage_title

Визначити оптимальну діагностичну методику для контролю ефективності подвійної трансплантації (DWI МРТ, РЕТ-КТ) при наявності резидуальної пухлини та дослідити ефективність подвійної трансплантації аутологічних гемопоетичних клітин при різних онкологічних захворюваннях у дітей.

Head

Klymniuk Hryhorii I., к.мед.н.

Registration Date

27-06-2025

Organization

National Cancer Institute

popup.description1

Improve the results of treatment of children with neuroblastoma, Ewing's sarcoma, brain tumors by double transplantation of autologous hematopoietic cells

popup.description2

The aim of the work is to improve the results of treatment of children with neuroblastoma, Ewing's sarcoma and brain tumors in children by double transplantation of autologous hematopoietic cells. Research methods are clinical, radiological, sonographic, morphological, molecular genetic, statistical. Equipment is Histos-5 histoprocessor, Milestone, Italy, NM325 microtome Thermo Scientific, Germany, 7500 Real-Time PCR Systems flow cytometer "Applied Biosystems", USA, ATL HDI-5000 ultrasound device "Philips" USA. The overall survival of transplanted patients is 42% (neuroblastoma) and 32.5% (Ewing's sarcoma) patients, while non-transplanted patients are 10% and 27.5% of patients, respectively. The optimal conditioning regimens of HVCT with autoTSPC in the treatment of neuroblastoma and Ewing's sarcoma in children are BuMel and MES. The introduction of the method of double transplantation of autologous hematopoietic cells statistically significantly increased the relapse-free survival of children with neuroblastoma by 8.3%. The overall survival of patients who underwent only one element of VDCT with autologous TSPC is 51.8%, relapse-free – 38.5%. The overall survival of patients who underwent double VDCT with autologous TSPC is 63.2%, relapse-free – 46.8%. The difference is statistically significant, p=0.02. The use of the method of double transplantation of autologous hematopoietic cells statistically significantly increased the overall survival of children with GM tumors by 33.3%. The overall 2-year survival rate of patients who underwent only one element of VTHT with autologous TSCPC is 50.0%, and two elements – 83.3% (p=0.02). 

Product Description

popup.authors

Pavlyk Serhii V.
Shaida Elen V.

popup.nrat_date

2025-06-27